Immunomedics Reports Clinical Results of Pretargeted Radioimmunotherapy of Colorectal Cancer

Immunomedics, Inc. IMMU today reported that colorectal cancer can be safely, specifically and rapidly targeted with TF2 bispecific antibody and a radiolabeled peptide, with limited toxicity to the patient. Results from the Phase I clinical study were reported at the 2012 Annual Meeting of the American Association for Cancer Research by investigators from the Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands. TF2 is a bispecific antibody created by the Company's patented Dock-and-Lock (DNL) conjugation technology. In addition to targeting the carcinoembryonic antigen (CEA or CEACAM5) expressed by many human cancers, TF2 has been engineered to recognize a small peptide that carries radioactivity. This allows the injection of radioactivity to be separated from the administration of the tumor-targeting bispecific antibody, a concept known as pretargeting.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: NewsFDAEvents
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!